Literature DB >> 20857901

Proteomic molecular portrait of interface zone in breast cancer.

Suki Kang1, Min Ju Kim, Heejung An, Baek Gil Kim, Yoon Pyo Choi, Kyu Sub Kang, Ming-Qing Gao, Hangran Park, Hyung Jin Na, Hye Kyung Kim, Hae Ree Yun, Dong Su Kim, Nam Hoon Cho.   

Abstract

Surgical tumor margins are intended to encompass residual tumor cells but may not always accurately delineate the boundary between tumor and normal tissue. Efforts to define tumor margins based on molecular analysis have achieved limited success. Furthermore, no clinical trials have addressed the scope of the tumor microenvironment. Here, we considered the tumor cell population and surrounding microenvironment in delineating tumor margins, classifying breast cancer into tumor and normal zones, and introducing the concept of an interface zone, the region between the invading tumor front and normal tissue, which develops during tumor invasion and metastasis through remodeling of the tumor microenvironment. Pathological signatures of invasion markers in tumor tissues are most dynamic within the invading tumor front. We compared protein profiles of tumor, normal, and interface zones using MALDI-MS. Proteins upregulated in the interface zone were identified by peptide mass fingerprinting and confirmed by database searching with chemically assisted MALDI-PSD spectra. Upregulation was confirmed for RhoGDIα, CAPG, WDR1, and CK8 by Western and immunohistochemical analyses. Our results demonstrate that the molecular profile of the interface zone is unique and suggest that upregulation of proteins here may be related to progression and metastasis of breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20857901     DOI: 10.1021/pr1004532

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  15 in total

1.  Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse.

Authors:  Marcin Imielinski; Sangwon Cha; Tomas Rejtar; Elizabeth A Richardson; Barry L Karger; Dennis C Sgroi
Journal:  Mol Cell Proteomics       Date:  2012-01-12       Impact factor: 5.911

Review 2.  Functions of actin-interacting protein 1 (AIP1)/WD repeat protein 1 (WDR1) in actin filament dynamics and cytoskeletal regulation.

Authors:  Shoichiro Ono
Journal:  Biochem Biophys Res Commun       Date:  2017-10-19       Impact factor: 3.575

3.  High expression of WDR1 in primary glioblastoma is associated with poor prognosis.

Authors:  Hanchong Xu; Yihong Chen; Cong Tan; Tao Xu; Yong Yan; Rong Qin; Qilin Huang; Chengyin Lu; Chun Liang; Yicheng Lu; Hongxiang Wang; Juxiang Chen
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK.

Authors:  Ying Fu; Xiuzhi Zhang; Xujun Liang; Yongheng Chen; Zhuchu Chen; Zhefeng Xiao
Journal:  World J Surg Oncol       Date:  2022-10-19       Impact factor: 3.253

5.  Function of the macrophage-capping protein in colorectal carcinoma.

Authors:  Wei Wu; Jingdi Chen; Qianshan Ding; Sheng Yang; Jianping Wang; Honggang Yu; Jun Lin
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

6.  WDR1 predicts poor prognosis and promotes cancer progression in hepatocellular carcinoma.

Authors:  Linhui Zheng; Fang Hu; Jiaxi Li; Zhiwen Wang; Li Deng; Benping Xiao; Jianfeng Li; Xiong Lei
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

7.  A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis.

Authors:  Katrien Van Impe; Jonas Bethuyne; Steven Cool; Francis Impens; David Ruano-Gallego; Olivier De Wever; Berlinda Vanloo; Marleen Van Troys; Kathleen Lambein; Ciska Boucherie; Evelien Martens; Olivier Zwaenepoel; Gholamreza Hassanzadeh-Ghassabeh; Joël Vandekerckhove; Kris Gevaert; Luis Ángel Fernández; Niek N Sanders; Jan Gettemans
Journal:  Breast Cancer Res       Date:  2013-12-13       Impact factor: 6.466

8.  CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.

Authors:  Jules A Westbrook; David A Cairns; Jianhe Peng; Valerie Speirs; Andrew M Hanby; Ingunn Holen; Steven L Wood; Penelope D Ottewell; Helen Marshall; Rosamonde E Banks; Peter J Selby; Robert E Coleman; Janet E Brown
Journal:  J Natl Cancer Inst       Date:  2016-01-12       Impact factor: 13.506

9.  Macrophage capping protein CapG is a putative oncogene involved in migration and invasiveness in ovarian carcinoma.

Authors:  J Glaser; M H D Neumann; Qi Mei; B Betz; N Seier; I Beyer; T Fehm; H Neubauer; D Niederacher; M C Fleisch
Journal:  Biomed Res Int       Date:  2014-04-02       Impact factor: 3.411

10.  Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.

Authors:  Nagireddy Putluri; Suman Maity; Ramakrishna Kommagani; Ramakrishna Kommangani; Chad J Creighton; Vasanta Putluri; Fengju Chen; Sarmishta Nanda; Salil Kumar Bhowmik; Atsushi Terunuma; Tiffany Dorsey; Agostina Nardone; Xiaoyong Fu; Chad Shaw; Tapasree Roy Sarkar; Rachel Schiff; John P Lydon; Bert W O'Malley; Stefan Ambs; Gokul M Das; George Michailidis; Arun Sreekumar
Journal:  Neoplasia       Date:  2014-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.